Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

Prospective Observational Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02123199

Acronym

INHALE

Enrollment

103

Registered

2014-04-25

Start date

2012-04-30

Completion date

Unknown

Last updated

2014-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD

Brief summary

A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.

Interventions

DRUGIndacaterol (Onbrez®) /QAB149

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes

Exclusion criteria

* Patients who are currently receiving other maintenance therapy (except LAMA) for COPD. * Patients previously prescribed Indacaterol.

Design outcomes

Primary

Measure	Time frame
Change in COPD assessment Test (CAT Score) at 6-8 weeks after the initiation of indacaterol	6-8 weeks

Secondary

Measure	Time frame
Change in COPD Assessment test (CAT) score at 6 months after the initiation of indacaterol	6 months
Impact of indacaterol on patients' lies at 6 - 8 weeks after the initiation of indacaterol.	6-8 weeks
Physician Global Evaluation of Treatment effectiveness (GETE) at 6-8 weeks and 6 months.	6-8 weeks and 6 months
Patient Global Evaluation of Treatment effectiveness (GETE) at 6 months	6 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026